Neumora Therapeutics, Inc.
490 Arsenal Way
10 articles about Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. today announced the initiation of a Phase 1 single ascending dose / multiple ascending dose study evaluating NMRA-266 in healthy adult participants.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company redefining neuroscience drug development, announced financial results for the third quarter ended September 30, 2023 and provided a general business update.
Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will participate in two investor conferences in November.
The two biotech companies announced initial public offering pricing Thursday, respectively, with shares beginning trading Friday and valued at more than $560 million cumulatively.
In the largest biotech Series C financing so far this year, Generate:Biomedicines raised $273 million, while Neumora and RayzeBio announced IPO pricing valued at more than $560 million combined.
Neumora Therapeutics, Inc. (“Neumora”), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the pricing of its initial public offering of 14,710,000 shares of its common stock at a price to the public of $17.00 per share.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company redefining neuroscience drug development, announced the appointment of Henry Gosebruch as president and chief executive officer and a member of the Company’s board.
Neumora Therapeutics Announces Initiation of Phase 3 Clinical Program for Navacaprant (NMRA-140) in Major Depressive Disorder
Neumora Therapeutics, Inc. announced the planned initiation of the KOASTAL Program, a Phase 3 pivotal clinical program designed to evaluate the efficacy and safety of navacaprant monotherapy for the treatment of major depressive disorder.
Less than two years after launch, the startup posts positive Phase II results and heads into Phase III trials for major depressive disorder with a new CEO.
BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America.